Theravance Biopharma Statistics
Total Valuation
TBPH has a market cap or net worth of $456.61 million. The enterprise value is $418.08 million.
Important Dates
The next estimated earnings date is Monday, May 12, 2025, after market close.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TBPH has 49.47 million shares outstanding. The number of shares has decreased by -11.67% in one year.
| Current Share Class | 49.47M |
| Shares Outstanding | 49.47M |
| Shares Change (YoY) | -11.67% |
| Shares Change (QoQ) | +0.55% |
| Owned by Insiders (%) | 7.81% |
| Owned by Institutions (%) | 41.52% |
| Float | 21.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.00 |
| Forward PS | 4.56 |
| PB Ratio | 2.60 |
| P/TBV Ratio | 2.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.02, with a Debt / Equity ratio of 0.28.
| Current Ratio | 5.02 |
| Quick Ratio | 4.89 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.67 |
Financial Efficiency
Return on equity (ROE) is -29.04% and return on invested capital (ROIC) is -10.88%.
| Return on Equity (ROE) | -29.04% |
| Return on Assets (ROA) | -7.21% |
| Return on Invested Capital (ROIC) | -10.88% |
| Return on Capital Employed (ROCE) | -13.18% |
| Revenue Per Employee | $663,722 |
| Profits Per Employee | -$581,629 |
| Employee Count | 97 |
| Asset Turnover | 0.17 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TBPH has paid $11.80 million in taxes.
| Income Tax | 11.80M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.44% in the last 52 weeks. The beta is 0.15, so TBPH's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | +2.44% |
| 50-Day Moving Average | 9.38 |
| 200-Day Moving Average | 8.99 |
| Relative Strength Index (RSI) | 46.44 |
| Average Volume (20 Days) | 202,516 |
Short Selling Information
The latest short interest is 3.94 million, so 7.96% of the outstanding shares have been sold short.
| Short Interest | 3.94M |
| Short Previous Month | 4.01M |
| Short % of Shares Out | 7.96% |
| Short % of Float | 18.64% |
| Short Ratio (days to cover) | 11.78 |
Income Statement
In the last 12 months, TBPH had revenue of $64.38 million and -$56.42 million in losses. Loss per share was -$1.15.
| Revenue | 64.38M |
| Gross Profit | 26.74M |
| Operating Income | -42.44M |
| Pretax Income | -38.22M |
| Net Income | -56.42M |
| EBITDA | -40.73M |
| EBIT | -42.44M |
| Loss Per Share | -$1.15 |
Full Income StatementBalance Sheet
The company has $88.35 million in cash and $49.82 million in debt, giving a net cash position of $38.53 million or $0.78 per share.
| Cash & Cash Equivalents | 88.35M |
| Total Debt | 49.82M |
| Net Cash | 38.53M |
| Net Cash Per Share | $0.78 |
| Equity (Book Value) | 175.55M |
| Book Value Per Share | 3.55 |
| Working Capital | 128.98M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$11.54 million and capital expenditures -$332,000, giving a free cash flow of -$11.87 million.
| Operating Cash Flow | -11.54M |
| Capital Expenditures | -332,000 |
| Free Cash Flow | -11.87M |
| FCF Per Share | -$0.24 |
Full Cash Flow StatementMargins
Gross margin is 41.53%, with operating and profit margins of -65.91% and -87.63%.
| Gross Margin | 41.53% |
| Operating Margin | -65.91% |
| Pretax Margin | -69.30% |
| Profit Margin | -87.63% |
| EBITDA Margin | -63.26% |
| EBIT Margin | -65.91% |
| FCF Margin | n/a |
Dividends & Yields
TBPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 11.67% |
| Shareholder Yield | n/a |
| Earnings Yield | -12.36% |
| FCF Yield | -2.60% |
Analyst Forecast
The average price target for TBPH is $13.75, which is 48.97% higher than the current price. The consensus rating is "Buy".
| Price Target | $13.75 |
| Price Target Difference | 48.97% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 30.87% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TBPH has an Altman Z-Score of -2.11 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.11 |
| Piotroski F-Score | 3 |